Savant Capital LLC Purchases 156 Shares of Biogen Inc. (NASDAQ:BIIB)

Savant Capital LLC increased its position in shares of Biogen Inc. (NASDAQ:BIIB) by 7.0% during the fourth quarter, HoldingsChannel.com reports. The fund owned 2,369 shares of the biotechnology company’s stock after acquiring an additional 156 shares during the period. Savant Capital LLC’s holdings in Biogen were worth $613,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. OFI Invest Asset Management bought a new position in shares of Biogen in the 3rd quarter worth $26,000. Gladius Capital Management LP bought a new position in shares of Biogen in the 3rd quarter worth $28,000. KB Financial Partners LLC increased its holdings in shares of Biogen by 105.1% in the 3rd quarter. KB Financial Partners LLC now owns 121 shares of the biotechnology company’s stock worth $31,000 after buying an additional 62 shares during the last quarter. CVA Family Office LLC bought a new position in shares of Biogen in the 4th quarter worth $36,000. Finally, Baker Avenue Asset Management LP increased its holdings in shares of Biogen by 215.5% in the 3rd quarter. Baker Avenue Asset Management LP now owns 183 shares of the biotechnology company’s stock worth $47,000 after buying an additional 125 shares during the last quarter. Institutional investors own 87.93% of the company’s stock.

Analyst Ratings Changes

Several research firms recently commented on BIIB. Bank Of America (Bofa) reduced their target price on shares of Biogen from $290.00 to $280.00 and set a “neutral” rating on the stock in a report on Monday, February 12th. Wells Fargo & Company lowered shares of Biogen from an “overweight” rating to an “equal weight” rating and reduced their target price for the company from $315.00 to $240.00 in a report on Wednesday, February 14th. BMO Capital Markets reduced their target price on shares of Biogen from $295.00 to $285.00 and set an “outperform” rating on the stock in a report on Wednesday, February 14th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $311.00 target price on shares of Biogen in a report on Tuesday, February 20th. Finally, UBS Group reduced their target price on shares of Biogen from $250.00 to $214.00 and set a “neutral” rating on the stock in a report on Wednesday, April 17th. Ten research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. According to data from MarketBeat, Biogen has a consensus rating of “Moderate Buy” and an average price target of $290.92.

Insider Buying and Selling

In other Biogen news, insider Priya Singhal sold 419 shares of the firm’s stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $239.45, for a total transaction of $100,329.55. Following the completion of the sale, the insider now directly owns 4,516 shares in the company, valued at approximately $1,081,356.20. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, Director Eric K. Rowinsky acquired 455 shares of Biogen stock in a transaction that occurred on Thursday, February 15th. The stock was bought at an average price of $222.54 per share, for a total transaction of $101,255.70. Following the completion of the transaction, the director now owns 20,629 shares in the company, valued at $4,590,777.66. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Priya Singhal sold 419 shares of the business’s stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $239.45, for a total value of $100,329.55. Following the sale, the insider now owns 4,516 shares of the company’s stock, valued at $1,081,356.20. The disclosure for this sale can be found here. Insiders sold a total of 882 shares of company stock worth $202,030 in the last three months. 0.60% of the stock is owned by corporate insiders.

Biogen Stock Up 1.9 %

Shares of Biogen stock opened at $217.51 on Friday. The company has a debt-to-equity ratio of 0.41, a current ratio of 2.10 and a quick ratio of 1.32. The company has a 50-day moving average of $212.00 and a 200 day moving average of $232.09. The firm has a market cap of $31.67 billion, a price-to-earnings ratio of 27.15, a PEG ratio of 2.21 and a beta of -0.01. Biogen Inc. has a 1 year low of $189.44 and a 1 year high of $319.76.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings results on Wednesday, April 24th. The biotechnology company reported $3.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.45 by $0.22. The company had revenue of $2.29 billion during the quarter, compared to analyst estimates of $2.31 billion. Biogen had a net margin of 12.07% and a return on equity of 14.83%. Biogen’s quarterly revenue was down 7.0% compared to the same quarter last year. During the same period last year, the business earned $3.40 EPS. As a group, sell-side analysts anticipate that Biogen Inc. will post 15.6 earnings per share for the current fiscal year.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.